Shares of Galapagos NV (NASDAQ:GLPG - Get Free Report) have received a consensus recommendation of "Strong Sell" from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a sell rating and four have assigned a hold rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $26.75.
Several research firms have commented on GLPG. Morgan Stanley cut Galapagos from an "equal weight" rating to an "underweight" rating and cut their target price for the company from $31.00 to $22.00 in a research note on Friday, February 14th. TD Cowen cut shares of Galapagos from a "strong-buy" rating to a "strong sell" rating in a report on Thursday, January 9th. Barclays reaffirmed an "underweight" rating on shares of Galapagos in a research report on Thursday, January 23rd. Finally, Kepler Capital Markets cut shares of Galapagos from a "hold" rating to a "reduce" rating in a research report on Wednesday, November 20th.
Get Our Latest Stock Report on GLPG
Galapagos Trading Up 0.1 %
Shares of NASDAQ:GLPG traded up $0.03 during midday trading on Tuesday, reaching $26.58. 187,592 shares of the company were exchanged, compared to its average volume of 301,073. Galapagos has a fifty-two week low of $22.36 and a fifty-two week high of $35.06. The stock has a fifty day simple moving average of $25.29 and a two-hundred day simple moving average of $27.14.
Institutional Investors Weigh In On Galapagos
Institutional investors and hedge funds have recently modified their holdings of the company. R Squared Ltd bought a new stake in Galapagos in the fourth quarter valued at approximately $26,000. GAMMA Investing LLC lifted its holdings in Galapagos by 77.4% during the 4th quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company's stock valued at $61,000 after purchasing an additional 974 shares during the last quarter. QRG Capital Management Inc. bought a new position in Galapagos during the third quarter worth $247,000. BNP Paribas Financial Markets increased its holdings in shares of Galapagos by 45.9% in the fourth quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company's stock valued at $247,000 after purchasing an additional 2,824 shares during the last quarter. Finally, Erste Asset Management GmbH bought a new position in shares of Galapagos in the third quarter valued at about $410,000. 32.46% of the stock is owned by institutional investors.
About Galapagos
(
Get Free ReportGalapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Featured Stories

Before you consider Galapagos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galapagos wasn't on the list.
While Galapagos currently has a Strong Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.